American Heart Association

A study by the University of Arizona and UC Davis Health identified PIP2 as a new target for treating atrial fibrillation, the most common type of irregular heart rhythm. The research, published in the Proceedings of the National Academy of Sciences, explored how PIP2 regulates the SK2 channel, offering potential for novel inhibitors to treat cardiac arrhythmias.

An Apple Watch detected atrial fibrillation in a user, leading to diagnosis. The FDA approved it for sleep apnea detection, using PPG and an accelerometer. Apple's AirPods Pro 2 also received FDA approval as over-the-counter hearing aids.

New study identifies PIP2 lipid as a key regulator of SK2 channels, offering potential for AFib therapy development.

BridgeBio Pharma to present 42-month outcomes data from ATTRibute-CM study at AHA Scientific Sessions in Chicago, Nov 16-18, 2024, including a featured science oral presentation on acoramidis' effects in ATTR-CM.

Lecanemab, approved for Alzheimer disease, showed cognitive decline reduction in trials but poses risks, especially with cardiovascular disease and anticoagulant use. Caution advised for such patients, with ongoing research needed on real-world performance and side effect mitigation.

Cardiovascular diseases and stroke are leading causes of death worldwide. Researchers emphasize the need for diverse clinical trial participants to advance understanding and treatment. Women with atrial fibrillation face higher stroke risk than men, and cardiovascular disease prevalence is highest among non-Hispanic Blacks. The Librexia program, enrolling 50,000 patients across three trials, aims to address these gaps by recruiting women and diverse populations.

Black American infants with congenital heart disease have a higher risk of death by age 1 compared to white infants, despite overall U.S. death rates decreasing by 25% from 2005 to 2019.

Finerenone extends event-free survival by up to 3 years in HFmrEF or HFpEF patients, according to a prespecified analysis of the FINEARTS-HF trial, supporting its role in modifying clinical event risks.

Drs. Onyeka Obioha-Lolange and Merije Chukumerije emphasize the necessity of diverse clinical trials for equitable healthcare, highlighting the gaps in dermatology and cardiology research due to lack of representation. They advocate for systemic changes to make diversity in clinical trials the norm.

Body Roundness Index (BRI) better predicts heart disease risk than BMI, with a 163% increased risk for high BRI and 61% for moderate BRI over six years, according to a study published in the Journal of the American Heart Association.